EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Pamela S Gaskin iD, Peter S Chami

Obesity Reviews · 2026

DOI: 10.1111/obr.70145 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Obesity Reviews, 2026. Verfasst von Pamela S Gaskin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Incretins, Obesity. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include higher baseline body weight, BMI, HbA1c, and insulin resistance. Genetic factors, such as variants in the GLP1R gene, may also influence treatment outcomes. Metabolic health status, particularly glycemic control and insulin sensitivity, plays a crucial role in determining weight loss efficacy. Adherence to medication regimens is strongly associated with treatment success, with each additional month of treatment linked to greater weight loss. Lifestyle factors, including dietary habits and physical activity, can modulate responses to these medications. Emerging evidence suggests that gut microbiome composition may mediate weight loss outcomes. Demographic factors such as male sex and older age are associated with lower weight loss responses. Understanding these predictors is essential for optimizing treatment strategies, setting realistic expectations, and moving towards a precision medicine approach in obesity care. Further research is needed to validate these findings in diverse populations and develop practical tools for clinical decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsObesityWeight LossGlucagon-Like Peptide-1 Receptor AgonistsHumansDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

GLP1 and GIP analogslow weight loss responseobesityweight loss

Substanzen

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1IncretinsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados.
  • Faculty of Pure and Applied Sciences, University of the West Indies, Bridgetown, Barbados.
  • Faculty of Medical Sciences, The Warren Alpert Medical School, Bridgetown, Barbados.

ORCID-Profile: Pamela S Gaskin

Zitieren

APA

Gaskin, P. S., & Chami, P. S. (2026). Low Weight Loss Response to Incretin Analogs: A Systematic Review. Obesity Reviews. https://doi.org/10.1111/obr.70145

Vancouver

Gaskin PS, Chami PS. Low Weight Loss Response to Incretin Analogs: A Systematic Review. Obesity Reviews. 2026. doi:10.1111/obr.70145

BibTeX
@article{Gaskin2026,
  author = {Gaskin, Pamela S and Chami, Peter S},
  title = {Low Weight Loss Response to Incretin Analogs: A Systematic Review},
  journal = {Obesity Reviews},
  year = {2026},
  doi = {10.1111/obr.70145}
}
Kostenlos starten →